Used in pharmaceutical research as a key intermediate in the synthesis of targeted protein degraders, particularly cereblon E3 ligase modulators. Its structure enables selective binding to cereblon, making it valuable in developing PROTACs (proteolysis-targeting chimeras) for cancer and inflammatory diseases. The compound's bromo and isoindolinone groups facilitate conjugation with target-binding ligands, enhancing degradation of disease-related proteins. Also explored in medicinal chemistry for optimizing pharmacokinetic properties in small molecule therapeutics.